Evidence map›Paper›PMID 40273497›Full record

ArticleClinics (Sao Paulo, Brazil)2025

TeleHCV: A single-visit protocol and minimal passive remote monitoring are sufficient to achieve high SVR with a sofosbuvir-velpatasvir regimen.

Jerônimo De Conto Oliveira, Fernando Comunello Schacher, Marisa Boff Costa, Maurício Godinho Kolling, Raquel Boff Costa, Henrique Cabral Scherer, Paula Martins Fernandes, Natan Katz, Marcelo Rodrigues Gonçalves, Dimitris Varvaki Rados and 1 more

Registry-linked trialAbstract readEquivalence Trial
In one paragraph

Article in Clinics (Sao Paulo, Brazil), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04039698 (Monitoring of Hepatitis C Therapy Using Telemedicine in a Simplified Protocol With Pangenotypic Regimen in Non-cirrhotic Patients - a Single Group Clinical Trial in the National Public Health System in Brazil), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04039698 naunknown statusnot on this map

Monitoring of Hepatitis C Therapy Using Telemedicine in a Simplified Protocol With Pangenotypic Regimen in Non-cirrhotic Patients - a Single Group Clinical Trial in the National Public Health System in Brazil

TypeinterventionalSponsorHospital de Clinicas de Porto AlegreRan2019 to 2021Enrolled144ConditionsChronic Hepatitis CArmsTelemedicine, Velpatasvir/Sofosbuvir
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jerônimo De Conto OliveiraGraduate Program in Gastroenterology and Hepatology, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil; GI/Liver Unit, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil; Núcleo de Telessaúde Técnico Científico do Rio Grande do Sul (TelessaúdeRS-UFRGS), Porto Alegre, RS, Brazil; Project ECHO Liver Diseases Clinic, HCPA, Porto Alegre, Brazil.
Fernando Comunello SchacherGraduate Program in Gastroenterology and Hepatology, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.
Marisa Boff CostaGraduate Program in Gastroenterology and Hepatology, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.
Maurício Godinho KollingNúcleo de Telessaúde Técnico Científico do Rio Grande do Sul (TelessaúdeRS-UFRGS), Porto Alegre, RS, Brazil.
Raquel Boff CostaGraduate Program in Gastroenterology and Hepatology, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.
Henrique Cabral SchererNúcleo de Telessaúde Técnico Científico do Rio Grande do Sul (TelessaúdeRS-UFRGS), Porto Alegre, RS, Brazil.
Paula Martins FernandesNúcleo de Telessaúde Técnico Científico do Rio Grande do Sul (TelessaúdeRS-UFRGS), Porto Alegre, RS, Brazil.
Natan KatzNúcleo de Telessaúde Técnico Científico do Rio Grande do Sul (TelessaúdeRS-UFRGS), Porto Alegre, RS, Brazil; Universidade Federal do Rio Grande do Sul, Faculdade de Medicina, Porto Alegre, RS, Brazil.
Marcelo Rodrigues GonçalvesNúcleo de Telessaúde Técnico Científico do Rio Grande do Sul (TelessaúdeRS-UFRGS), Porto Alegre, RS, Brazil; Universidade Federal do Rio Grande do Sul, Faculdade de Medicina, Porto Alegre, RS, Brazil.
Dimitris Varvaki RadosNúcleo de Telessaúde Técnico Científico do Rio Grande do Sul (TelessaúdeRS-UFRGS), Porto Alegre, RS, Brazil; Universidade Federal do Rio Grande do Sul, Faculdade de Medicina, Porto Alegre, RS, Brazil.
Mário Reis Álvares-da-SilvaGraduate Program in Gastroenterology and Hepatology, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil; GI/Liver Unit, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil; Project ECHO Liver Diseases Clinic, HCPA, Porto Alegre, Brazil; Universidade Federal do Rio Grande do Sul, Faculdade de Medicina, Porto Alegre, RS, Brazil; World Gastroenterology Organisation Porto Alegre Hepatology Training Center, Porto Alegre, RS, Brazil; Researcher, CNPq, Brazil. Electronic address: marioreis@live.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimChronic Hepatitis-C Virus (HCV) treatment has evolved significantly in recent years with Direct-Acting Antivirals (DAAs). The traditional care cascade includes several steps that limit its impact, and simplification protocols have emerged. Therefore, the authors explore a simplified treatment strategy for HCV in a healthcare system with limited access to specialized care. SUBJECT AND

methodsChronic HCV, DAA-naïve patients waiting for in-person specialized care were invited to a single-arm non-inferiority trial to evaluate a simplified treatment protocol with a single face-to-face appointment and minimal monitoring of antiviral therapy. The unique visit consisted of an HCV presentation followed by individual medical consultation, blood tests, and delivery of sofosbuvir-velpatasvir pills for a 12-week treatment. Patients were remotely monitored without scheduled on-treatment appointments or phone calls. After treatment, teleconsultation using video was offered. The primary outcome was Sustained Virological Response (SVR) 12-weeks post-treatment. It was analyzed with Intention-To-Treat (ITT) and Per-Protocol (PP) approaches. CLINICALTRIALS: gov: NCT04039698.

resultsThe authors included 144 patients, of which 54.2 % were male, mean age was 52 years. Most individuals (84.7 %) had an APRI score < 1. All patients received at least one dose of DAA, 139 completed antiviral therapy, and 131 had SVR evaluation. The ITT SVR rate was 90.3 % (130/144 patients; 95 % CI 84.2 %‒94.6 %), and the PP SVR was 99.2 % (130/131 patients; 95 % CI 95.8 %‒100 %). Eighty-three adverse events were reported, and 93 % were handled with remote care.

conclusionThis simplified strategy achieved a high SVR rate in a population with restricted access to specialized care. Telehealth tools and minimal monitoring are promising components for policies aimed at HCV elimination.

Indexed as

Antiviral AgentsCarbamatesHepatitis C, ChronicHeterocyclic Compounds, 4 or More RingsSofosbuvirAdultAgedBenzimidazolesBenzopyransDrug CombinationsFemaleHumansMaleMiddle AgedSustained Virologic ResponseTelemedicineAntiviral AgentsBenzimidazolesBenzopyransCarbamatesDrug CombinationsHeterocyclic Compounds, 4 or More RingsSofosbuvirsofosbuvir-velpatasvir drug combinationvelpatasvirCare cascadeDirect-acting antiviralsHepatitis CMicroeliminationMinimal monitoringPublic healthTelehealthTelemedicineTreatmentViral hepatitis

Identifiers

PMID40273497
PMCPMC12051514

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.